fda shortage list tirzepatide Eli Lilly's Weight-Loss, Diabetes Drug Shortages Are Over, Says Eli Lilly's tirzepatide is off

By stimulating both GIP and GLP-1 pathways, it promotes insulin secretion, suppresses glucagon release, and delays gastric emptying

This keeps blood sugar levels stable without causing dangerous lows

Improper storage can reduce the medication's potency and compromise your weight loss results, making it essential to follow precise guidelines for keeping your injections safe

The most common gastrointestinal side effects include: Nausea : Reported in 15-44% of patients (higher rates at Wegovy 2.4 mg), typically most pronounced during dose escalation Diarrhea : Affects approximately 8-30% of users, ranging from mild to moderate severity Vomiting : Occurs in 5-24% of patients (higher rates at Wegovy 2.4 mg), often associated with rapid dose increases Abdominal pain : Experienced by 5-20% of patients, usually described as cramping or discomfort Constipation : Paradoxically affects 3-24% despite the medication's effects on motility Dyspepsia and gastroesophageal reflux : Related to delayed gastric emptying These effects result from semaglutide's pharmacologic action on GLP-1 receptors throughout the gastrointestinal tract